Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alglucosidase alfa in Chinese infants with infantile-onset Pompe disease
2021-004047-25Phase 4
- Sponsor
- Sanofi
- Start
- Jul 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Survival.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2021-004047-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004047-25.